-
Australia Opens The Door for SKY-0515: Skyhawk Seeks Provisional Approval for Its Oral HD Drug
Latest News
-
The road ahead for uniQure: FDA says more data needed for AMT-130 gene therapy
⏱️ 10 min read | The FDA wants more data before approving AMT-130 for Huntington’s disease in the U.S. On March 2026, uniQure shared in an update that current Phase 1/2 data weren’t enough for the agency. A new randomized, sham-controlled trial may be required.
-
EuroBuzz News: Day 3
EuroBuzz news: Day 3. Ed and Jeff reporting from the European Huntington’s Disease Network 2012 meeting in Stockholm
-
EuroBuzz News: Day 2
EuroBuzz news: Day 2. Ed and Jeff reporting from the European Huntington’s Disease Network 2012 meeting in Stockholm
-
EuroBuzz News: Day 1
EuroBuzz news: Day 1. Ed and Jeff reporting from the European Huntington’s Disease Network meeting in Stockholm
-
Coming Soon: EuroBuzz 2012
Coming soon from the Euro-HD Network Meeting in Stockholm: EuroBuzz!
-
Lithium with a twist gets second chance for HD
Lithium gets a second chance in HD – with a new chemical delivery method, tested in Huntington’s disease mice
-
High-power brain scans reveal sodium changes in HD
A new brain scanning technique reveals high sodium levels in HD brains. How might this help clinical trials?
-
Mapping the neighborhood: huntingtin's new protein partners
Study of huntingtin protein's 'neighbors' reveals dozens of new drug development targets
-
Does the HD mutation affect children's growth?
A small study suggests kids with the HD mutation but no symptoms have subtle differences in growth. What does it mean
-
'Induced' stem cells make exciting advances
Stem cells from HD patients: becoming important tools for researchers – and now correcting the HD mutation in the lab
-
ASO gene silencing reaches further, lasts longer
Silencing the Huntingtin gene using ASO drugs reaches further, lasts longer and is safe. Human trial soon?
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
